The use of dupilumab, an approved anti-inflammatory antibody-based treatment, worked to ease itching, known medically as pruritus, in a young woman with Alagille syndrome…
News
CHOLESTASIS
NewsLivmarli now approved in US for PFIC patients 1 year and older
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
CHOLANGITIS
NewsNGM Bio raises funds to launch clinical trial of aldafermin for PSC
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…
CHOLESTASIS
NewsCertain fatty molecules may help diagnose liver disease in pregnancy
Blood levels of certain fatty molecules, called short-chain fatty acids (SCFAs), in pregnant women may help diagnose intrahepatic cholestasis of pregnancy (ICP), according to…
FATTY LIVER DISEASE
NewsAmerican Liver Foundation aiming to improve care for patients
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
BILIARY ATRESIA
NewsGut bacterium B. longum linked to better biliary atresia outcomes
Levels of Bifidobacterium longum (B. longum), a well-known probiotic, in the gut are significantly reduced in children with biliary atresia, a study in Taiwan…
HEPATITIS
NewsWHO prequalifies 1st home test for hepatitis C
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV) in a home setting, marking…
CHOLANGITIS
NewsPSC treatment bexotegrast safe, eases liver scarring in early trial
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…
CHOLESTASIS
NewsPFIC therapy IN016 earns FDA’s rare pediatric disease designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to IN016, Innorna’s experimental therapy that aims to address the root…
Recent Posts
- Experimental ICP drug volixibat shows early promise for mothers, babies
- Celebrating a major milestone with a 5th birthday party for the ages
- In proof-of-concept trial, daily pill lowers blood, liver fat levels in MASLD
- Rare biliary atresia variant linked to better clinical outcomes: China study
- New test detects hepatitis B in 1 hour with a finger prick: Study